TNFSF11 and Familial prostate cancer: In June 2010, a new class of medications known as receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, specifically Denosumab, was approved by the FDA for treatment of osteoporosis (Prolia) and bony metastases from solid tumors such as breast and prostate cancer (Xgeva).